Literature DB >> 12406567

Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation.

Akira Kamijo1, Tomihisa Koshino, Masaaki Uesugi, Hironori Nitto, Tomoyuki Saito.   

Abstract

Using a model with external ligation of the thigh, the effect of ischemia-reperfusion injury on tumor growth and the activity of lung metastasis was investigated in mice inoculated a spontaneous murine osteosarcoma cell line (POS-1) in vivo. POS-1 cell suspension was inoculated into the right hind footpad of 70 mice. Four weeks after inoculation, the ipsilateral thigh was ligated for 3 h in 15 mice and the contralateral thigh in 15 mice. Another ten mice were inoculated with POS-1 without ligating the thigh. The number of metastatic foci on the lung surface 6 weeks after inoculation was 2.29+/-0.98 (mean+/-SE) foci/lungs in mice with ipsilateral ligation and 6.25+/-2.41 in mice with contralateral ligation, which were significantly lower than control (13.40+/-1.42 in mice no ligation) (P<0.01). The number of metastatic foci on the lung surface in mice with intraperitoneal injection of superoxide dismutase (SOD) and catalase was 3.25+/-0.65 (mean+/-SE) foci/lungs in mice with ligation which was significantly greater than that in mice without SOD and catalase injection 1.29+/-0.97 (P=0.04). Cell viability was 9.12+/-4.07% with 100 microM H(2)O(2) in 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. It revealed that at concentrations of 100 microM H(2)O(2) or higher was cytotoxic to POS-1. In cell invasion assay, the number of invading cells with 10 microM H(2)O(2) was 2.80+/-0.53 cells/field, which was significantly lower than control (5.93+/-0.18) (mean+/-SE), indicating that low-dose H(2)O(2) suppressed invasion of POS-1. These results suggested that reperfusion injury had selective cytotoxicity to POS-1 through producing reactive oxygen species. Activated oxygen was considered to inhibit the regional growth and the ability of lung metastasis of POS-1 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406567     DOI: 10.1016/s0304-3835(02)00433-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

Authors:  Gatien Moriceau; Benjamin Ory; Laura Mitrofan; Chiara Riganti; Frédéric Blanchard; Régis Brion; Céline Charrier; Séverine Battaglia; Paul Pilet; Marc G Denis; Leonard D Shultz; Jukka Mönkkönen; Françoise Rédini; Dominique Heymann
Journal:  Cancer Res       Date:  2010-10-22       Impact factor: 12.701

2.  Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Authors:  Naiara Martinez-Velez; Virginia Laspidea; Marta Zalacain; Ana Patiño-García; Marta M Alonso; Sara Labiano; Marc García-Moure; Montse Puigdelloses; Lucía Marrodan; Marisol Gonzalez-Huarriz; Guillermo Herrador; Daniel de la Nava; Iker Ausejo-Mauleon; Juan Fueyo; Candelaria Gomez-Manzano
Journal:  Mol Cancer Ther       Date:  2022-03-01       Impact factor: 6.261

3.  Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk.

Authors:  Kanji Mori; Frederic Blanchard; Celine Charrier; Severine Battaglia; Kosei Ando; Laurence Duplomb; Leonard D Shultz; Francoise Redini; Dominique Heymann
Journal:  Cancer Sci       Date:  2008-10-18       Impact factor: 6.716

4.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.

Authors:  François Lamoureux; Gaëlle Picarda; Julie Rousseau; Clothilde Gourden; Séverine Battaglia; Céline Charrier; Bruno Pitard; Dominique Heymann; Françoise Rédini
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

5.  Autologous tumor immunizing devascularization of an invasive colorectal cancer: A case report and literature review.

Authors:  Pavel Vašek; Josef Krajnik; David J Kopsky; Vladimir Kalina; Marek Frydrych
Journal:  Mol Clin Oncol       Date:  2016-09-21

6.  Tumour devascularisation as a potential immunotherapeutic strategy.

Authors:  Tomas Buchler; Pavel Vasek; Radek Spisek; Pavel Skrobanek; Vaclav Horejsi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

7.  Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.

Authors:  Guillermo Herrador-Cañete; Marta Zalacain; Sara Labiano; Virginia Laspidea; Montserrat Puigdelloses; Lucía Marrodan; Marc Garcia-Moure; Marisol Gonzalez-Huarriz; Javier Marco-Sanz; Iker Ausejo-Mauleon; Daniel de la Nava; Reyes Hernández-Osuna; Javier Martínez-García; Noelia Silva-Pilipich; Elisabeth Gurucega; Ana Patiño-García; Rubén Hernández-Alcoceba; Cristian Smerdou; Marta M Alonso
Journal:  Mol Ther Oncolytics       Date:  2022-07-09       Impact factor: 6.311

8.  Ischemia and reperfusion injury combined with cisplatin induces immunogenic cell death in lung cancer cells.

Authors:  Shuai Zhang; Yumei Li; Shuqing Liu; Pei Ma; Mengfei Guo; E Zhou; Limin Duan; Jinshuo Fan; Tingting Liao; Qi Tan; Xuan Wang; Feng Wu; Yang Jin
Journal:  Cell Death Dis       Date:  2022-09-03       Impact factor: 9.685

9.  Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

Authors:  Bérengère Gobin; Gatien Moriceau; Benjamin Ory; Céline Charrier; Régis Brion; Frederic Blanchard; Françoise Redini; Dominique Heymann
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.